AWH News and Press, Aspira Women's Health Inc. From 08/23/22

Aspira Women's Health ( NASDAQ: AWH ) priced its stock offering it released late on Monday at $9M, comprising the sale of 12M common shares priced at $0.75 apiece. The provider of diagnostic tests for gynecologic disease told the offering will also include the accompan...

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offerin...

Aspira Women’s Health ( NASDAQ: AWH ), a provider of diagnostic tests for gynecologic disease, lost ~23% in the post-market trading Monday after the company announced an underwritten public offering of its common stock and warrants. AWH has selected William Blai...

AUSTIN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has commenced an underwritten public offering of shares of its c...

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that it will host a key opinion leader (KOL) webinar on women’s health and...

Image source: The Motley Fool. Aspira Women's Health Inc. (NASDAQ: AWH) Q2 2022 Earnings Call Aug 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Aspira Women's Health Inc. (AWH) Q2 2022 Earnings Call Transcript...

Aspira Women's Health, Inc. (AWH) Q2 2022 Earnings Conference Call August 10, 2022 08:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Robert Beechey - Chief Financial Officer Ryan Phan - Chief Scientific Officer and Chief Ope...

Aspira Women’s Health press release ( NASDAQ: AWH ): Q2 GAAP EPS of -$0.07 in-line. Revenue of $2.06M (+14.4% Y/Y) misses by $0.34M . For further details see: Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M ...

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a d...

AUSTIN, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that the company will report its financial results for the second quarter ended J...